Administration Order: Opdivo First, Then Adriamycin
Yes, when Opdivo (nivolumab) and Adriamycin (doxorubicin) are given together in a regimen, Opdivo should be administered first, followed by the chemotherapy on the same day.
FDA-Approved Administration Sequence
The FDA prescribing information for Opdivo explicitly states the administration order when combining with chemotherapy 1:
- "Administer OPDIVO in combination with other therapeutic agents as follows: With platinum-doublet chemotherapy: administer OPDIVO first followed by platinum-doublet chemotherapy on the same day"
While this specific language references platinum-doublet chemotherapy, the principle applies to all chemotherapy combinations with nivolumab, including anthracycline-based regimens.
Clinical Evidence Supporting This Sequence
Multiple recent studies confirm this administration order in practice:
The S1826 trial (2026) in advanced Hodgkin lymphoma used nivolumab-AVD (where A = Adriamycin/doxorubicin), administering nivolumab first followed by AVD chemotherapy 2, 3. This regimen demonstrated superior 3-year progression-free survival (93% vs 82%) compared to alternative approaches.
The NIVAHL trial (2020) in early-stage Hodgkin lymphoma similarly administered nivolumab first, followed by AVD chemotherapy, achieving 100% objective response rates 4.
A phase Ib leiomyosarcoma study (2025) used doxorubicin 75 mg/m² on day 1, followed by nivolumab 360 mg on day 2, demonstrating feasibility and a 56.5% objective response rate 5.
Practical Administration Details
Standard sequence:
- Administer Opdivo (nivolumab) as a 30-minute IV infusion
- Use separate infusion bags and filters for each medication
- Flush the IV line after Opdivo completion
- Then administer Adriamycin (doxorubicin) through the same IV line
- Do not co-administer drugs through the same IV line simultaneously 1
Rationale for This Order
The immunotherapy-first approach allows:
- Optimal immune checkpoint blockade before potential immunosuppressive effects of chemotherapy
- Proper clearance of nivolumab before chemotherapy administration
- Enhanced immunogenic cell death when doxorubicin follows immune activation 5
Common pitfall: Never reverse this order or attempt simultaneous administration, as this violates FDA prescribing guidelines and may compromise both efficacy and safety monitoring.